Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Peringkat dalam Saham #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Harga Saham
$0.00047446
Kapitalisasi Pasar
$82.80
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-98.16%
Negara
FR
Perdagangan Neovacs S.A. (ALNEV)

Kategori

Riwayat dividen untuk Neovacs S.A. (ALNEV)
Saham Neovacs S.A. (simbol: ALNEV) telah membayar total 0 dividen.
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Pembayaran dividen untuk Neovacs S.A. (ALNEV) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (disesuaikan dengan stock split) Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Daftar semua pembayaran dividen
Tahun Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pembayaran dividen untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pembayaran dividen Negara
52.00%
DK
0.00%
US
5.00%
US
29.00%
BE
0.00%
NL